[1]Catenacci D, Tebbutt NC, Davidenko I, et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as firstline therapy in advanced METpositive gastric or gastrooesophageal junction cancer (RILOMET1): a randomised, doubleblind, placebocontrolled, phase 3 trial[J]. Lancet Oncol, 2017, 18(11): 1467-1482.
[2]Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3]Ilson DH, Tabernero J, Prokharau A, et al. Efficacy and safety of trifluridine/tipiracil treatment in patients with metastatic gastric cancer who had undergone gastrectomy: subgroup analyses of a randomized clinical trial[J]. JAMA Oncol, 2020, 6(1): e193531.
[4]Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention[J]. World J Gastrointest Oncol, 2012, 4(7): 156-169.
[5]Lamont BJ, Andrikopoulos S, Funkat A, et al. Peripheral insulin resistance develops in transgenic rats overexpressing phosphoenolpyruvate carboxykinase in the kidney[J]. Diabetologia, 2003, 46(10): 1338-1347.
[6]Watford M, Hod Y, Chiao YB, et al. The unique role of the kidney in gluconeogenesis in the chicken. The significance of a cytosolic form of phosphoenolpyruvate carboxykinase[J]. J Biol Chem, 1981, 256(19): 10023-10027.
[7]Yu S, Meng S, Xiang M, et al. Phosphoenolpyruvate carboxykinase in cell metabolism: Roles and mechanisms beyond gluconeogenesis[J]. Mol Metab, 2021, 53: 101257.
[8]Matsuoka H, Shima A, Kuramoto D, et al. Phosphoenolpyruvate carboxykinase, a key enzyme that controls blood glucose, is a target of retinoic acid receptorrelated orphan receptor α[J]. PLoS One, 2015, 10(9): e137955.
[9]Franckhauser S, Munoz S, Pujol A, et al. Increased fatty acid reesterification by PEPCK overexpression in adipose tissue leads to obesity without insulin resistance[J]. Diabetes, 2002, 51(3): 624-630.
[10]Montal ED, Dewi R, Bhalla K, et al. PEPCK coordinates the regulation of central carbon metabolism to promote cancer cell growth[J]. Mol Cell, 2015, 60(4): 571-583.
[11]Ma R, Ji T, Zhang H, et al. A Pck1directed glycogen metabolic program regulates formation and maintenance of memory CD8+ T cells[J]. Nat Cell Biol, 2018, 20(1): 21-27.
[12]Guo H, Chi Y, Chi N. Bioinformatis analysis reveals possible molecular mechanism of PXR on regulating ulcerative colitis[J]. Sci Rep, 2021, 11(1): 5428.
[13]Butler EB, Zhao Y, MunozPinedo C, et al. Stalling the engine of resistance: targeting cancer metabolism to overcome therapeutic resistance[J]. Cancer Res, 2013, 73(9): 2709-2717.
[14]Xu D, Wang Z, Xia Y, et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis[J]. Nature, 2020, 580(7804): 530-535.
[15]Liu MX, Jin L, Sun SJ, et al. Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma[J]. Oncogene, 2018, 37(12): 1637-1653.
[16]Shi L, An S, Liu Y, et al. PCK1 regulates glycolysis and tumor progression in clear cell renal cell carcinoma through LDHA[J]. Onco Targets Ther, 2020, 13: 2613-2627.
[17]Shao F, Bian X, Wang J, et al. Prognostic impact of PCK1 protein kinase activitydependent nuclear SREBP1 activation in nonsmallcell lung carcinoma[J]. Front Oncol, 2021, 11: 561247.
[18]Stark R, GuebreEgziabher F, Zhao X, et al. A role for mitochondrial phosphoenolpyruvate carboxykinase (PEPCKM) in the regulation of hepatic gluconeogenesis[J]. J Biol Chem, 2014, 289(11): 7257-7263.
[19]Cluntun AA, Lukey MJ, Cerione RA, et al. Glutamine metabolism in cancer: understanding the heterogeneity[J]. Trends Cancer, 2017, 3(3): 169-180.
[20]Yamaguchi N, Weinberg EM, Nguyen A, et al. PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis[J]. Elife, 2019, 8: e52135.
[21]Fattahi S, AmjadiMoheb F, Tabaripour R, et al. PI3K/AKT/mTOR signaling in gastric cancer: Epigenetics and beyond[J]. Life Sci, 2020, 262: 118513.
[22]Murugan AK. mTOR: Role in cancer, metastasis and drug resistance[J]. Semin Cancer Biol, 2019, 59: 92-111.
[23]GuerreroZotano A, Mayer IA, Arteaga CL. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment[J]. Cancer Metastasis Rev, 2016, 35(4): 515-524.
[24]Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance[J]. Semin Cancer Biol, 2019, 59: 147-160.
[25]Durn RV, Oppliger W, Robitaille AM, et al. Glutaminolysis activates RagmTORC1 signaling[J]. Mol Cell, 2012, 47(3): 349-358.
[26]Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer[J]. Nat Rev Cancer, 2018, 18(12): 744-757.
[27]Forest C, Beale E. New developments in nutrition and diabetes: glyceroneogenesis comes of age[J]. Biochimie, 2003, 85(12): 1195-1197.
|